Aegerion Pharmaceuticals, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2005-01-01
- Employees
- 236
- Market Cap
- -
- Website
- http://www.aegerion.com
Clinical Trials
21
Active:4
Completed:14
Trial Phases
4 Phases
Phase 1:6
Phase 2:6
Phase 3:4
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (17 trials with phase data)• Click on a phase to view related trials
Phase 1
6 (35.3%)Phase 2
6 (35.3%)Phase 3
4 (23.5%)Phase 4
1 (5.9%)Immunogenicity of Metreleptin in Patients With Generalized Lipodystrophy
- First Posted Date
- 2019-07-19
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Aegerion Pharmaceuticals, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT04026178
- Locations
- 🇺🇸
Univ. Alabama-Birmingham, Birmingham, Alabama, United States
🇺🇸Ochsner Clinic, New Orleans, Louisiana, United States
🇺🇸University of Michigan, Ann Arbor, Michigan, United States
Evaluate the Efficacy and Safety of Lomitapide in Pediatric Patients With Homozygous Familial Hypercholesterolemia on Stable Lipid-lowering Therapy
- First Posted Date
- 2016-05-09
- Last Posted Date
- 2018-02-22
- Lead Sponsor
- Aegerion Pharmaceuticals, Inc.
- Registration Number
- NCT02765841
Effects of Lomitapide on Carotid and Aortic Atherosclerosis
Withdrawn
- Conditions
- Homozygous Familial Hypercholesterolemia
- First Posted Date
- 2015-03-26
- Last Posted Date
- 2017-12-15
- Lead Sponsor
- Aegerion Pharmaceuticals, Inc.
- Registration Number
- NCT02399852
MEASuRE: Metreleptin Effectiveness And Safety Registry
- First Posted Date
- 2014-12-25
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- Aegerion Pharmaceuticals, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT02325674
- Locations
- 🇩🇪
Kinderkrankenhaus Auf der Bult, Hannover, Niedersachsen, Germany
🇺🇸University Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸City of Hope, Duarte, California, United States
Efficacy and Safety of Lomitapide in Japanese Patients With HoFH on Concurrent Lipid-Lowering Therapy
- First Posted Date
- 2014-06-24
- Last Posted Date
- 2018-10-10
- Lead Sponsor
- Aegerion Pharmaceuticals, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT02173158
- Prev
- 1
- 2
- 3
- 4
- Next
News
No news found